Development tracker
The peptide drug pipeline
Every peptide and incretin trial we track — sponsor, phase, status, molecule and expected readout. Built from public trial registry records and updated continuously. Free, no account needed.
251
trials tracked
146
readouts still ahead
132
currently recruiting
123
sponsors
Next readouts
Soonest first. Dates are the sponsor’s expected readout and move often.
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityRetatrutide, TirzepatideEli Lilly and Company · Phase 3Nov 2026
- A Study of BGM0504 in Participants With Type 2 DiabetesSemaglutideBrightGene Bio-Medical Technology Co., Ltd. · Phase 3Nov 2026
- Tirzepatide Impact Assessment StudySemaglutide, TirzepatideTexas Tech University · ObservationalNov 2026
- NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudySemaglutide, TirzepatideIstanbul Saglik Bilimleri University · ObservationalNov 2026
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesSemaglutide, TirzepatideIstanbul Saglik Bilimleri University · ObservationalNov 2026
- Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)KisspeptinNemours Children's Clinic · ObservationalDec 2026
- A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityTirzepatideEli Lilly and Company · Phase 1Dec 2026
- Oxytocin Pharmacokinetics and PharmacodynamicsOxytocinUniversity of Chicago · Phase 2Dec 2026
- Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMSemaglutideUniversity of California, San Diego · Phase 2Dec 2026
- GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver DiseaseSemaglutideInsel Gruppe AG, University Hospital Bern · ObservationalDec 2026
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyTirzepatideM.D. Anderson Cancer Center · ObservationalDec 2026
- Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenSemaglutide, TirzepatideMayo Clinic · Phase 4Dec 2026
Most active sponsors
- Eli Lilly and Company45
- Novo Nordisk A/S35
- Massachusetts General Hospital9
- Saniona7
- Hudson Biotech6
- Stephanie B. Seminara, MD5
- Wake Forest University Health Sciences4
- BrightGene Bio-Medical Technology Co., Ltd.3
By phase
- Phase 372
- Phase 272
- Phase 126
- Phase 423
- Observational58
All tracked trials
| Trial | Molecule | Sponsor | Phase | Status | Readout |
|---|---|---|---|---|---|
| Pre-approval Expanded Access of Retatrutide (LY3437943) | Retatrutide | Eli Lilly and Company | Observational | Active | — |
| PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study | Tirzepatide | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Dec 2034 |
| Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Tirzepatide | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 1 | Recruiting | Dec 2031 |
| Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes | Semaglutide | Yale University | Phase 1 | Recruiting | Oct 2031 |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Aug 2031 |
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation | Orforglipron | Massachusetts General Hospital | Phase 4 | Recruiting | Jul 2031 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | Tirzepatide | University of Texas Southwestern Medical Center | Phase 2 | Recruiting | Jul 2031 |
| GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Semaglutide, Tirzepatide | Miedziowe Centrum Zdrowia SA | Observational | Recruiting | Jan 2031 |
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Semaglutide | University of Massachusetts, Worcester | Phase 3 | Recruiting | Sept 2030 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide | Eli Lilly and Company | Phase 3 | Recruiting | Aug 2030 |
| Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib | Tirzepatide | University of Chicago | Phase 1 | Recruiting | Jun 2030 |
| Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea | Kisspeptin | Stephanie B. Seminara, MD | Phase 2 | Recruiting | May 2030 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease | Kisspeptin | Stephanie B. Seminara, MD | Phase 1 | Recruiting | May 2030 |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 3 | Recruiting | Mar 2030 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Mar 2030 |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Tirzepatide | University of Texas Southwestern Medical Center | Phase 2 | Recruiting | Feb 2030 |
| Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? | Semaglutide | Knut Mai | Observational | Recruiting | Feb 2030 |
| Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy | Cerebrolysin | Chang Gung Memorial Hospital | Phase 2 | Recruiting | Dec 2029 |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Tirzepatide | Eli Lilly and Company | Phase 3 | Recruiting | Dec 2029 |
| HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Semaglutide | Vanderbilt University Medical Center | Phase 2 | Recruiting | Nov 2029 |
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Tirzepatide | National Cancer Institute (NCI) | Phase 2 | Recruiting | Oct 2029 |
| PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses | Orforglipron | Massachusetts General Hospital | Phase 4 | Recruiting | Sept 2029 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | CagriSema | Novo Nordisk A/S | Phase 3 | Recruiting | Sept 2029 |
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Aug 2029 |
| A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Tirzepatide | Eli Lilly and Company | Phase 4 | Recruiting | Jul 2029 |
| Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery | Tirzepatide | Mario Musella MD | Observational | Recruiting | Jul 2029 |
| Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes | Semaglutide | Western University, Canada | Phase 4 | Recruiting | May 2029 |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Semaglutide | Novo Nordisk A/S | Phase 3 | Readout pending | Apr 2029 |
| Incretin Therapies in Obesity-related HFpEF | Tirzepatide | Columbia University | Phase 4 | Recruiting | Apr 2029 |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Retatrutide | Eli Lilly and Company | Phase 3 | Readout pending | Feb 2029 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | Semaglutide | The Methodist Hospital Research Institute | Phase 2 | Recruiting | Dec 2028 |
| Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Tirzepatide | Universidade do Porto | Phase 3 | Recruiting | Dec 2028 |
| Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Semaglutide | Population Health Research Institute | Phase 2 | Recruiting | Oct 2028 |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Semaglutide | Novo Nordisk A/S | Phase 3 | Recruiting | Oct 2028 |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Retatrutide | Eli Lilly and Company | Phase 3 | Readout pending | Oct 2028 |
| A Study of BGM0504 in Early T2DM With Obesity | Semaglutide | BrightGene Bio-Medical Technology Co., Ltd. | Phase 3 | Recruiting | Sept 2028 |
| A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication | Tirzepatide | Novo Nordisk A/S | Phase 1 | Recruiting | Sept 2028 |
| A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication | Semaglutide | Novo Nordisk A/S | Phase 1 | Recruiting | Sept 2028 |
| Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Semaglutide | Amgen | Phase 3 | Recruiting | Sept 2028 |
| A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice | Semaglutide | Novo Nordisk A/S | Observational | Recruiting | Aug 2028 |
| Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR) | Oxytocin | Stony Brook University | Phase 4 | Recruiting | Aug 2028 |
| MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease | Semaglutide | Oelisoa Andriankaja | Observational | Recruiting | Jul 2028 |
| Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Tirzepatide | Alaa Sada | Phase 2 | Recruiting | Jul 2028 |
| Tirzepatide in Obesity-Driven Endometrial Cancer | Tirzepatide | UNC Lineberger Comprehensive Cancer Center | Observational | Recruiting | Jul 2028 |
| Tirzepatide for the Treatment of Cannabis Use Disorder | Tirzepatide | Brigham and Women's Hospital | Phase 2 | Recruiting | Jun 2028 |
| Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke | Cerebrolysin | National Hospital of Acupuncture, Vietnam | Observational | Recruiting | Jun 2028 |
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | Tesamorelin | Massachusetts General Hospital | Phase 2 | Recruiting | Jun 2028 |
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Jun 2028 |
| Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial | Tirzepatide | yifang zhu | Phase 3 | Recruiting | May 2028 |
| Tirzepatide for Treatment of CCCA | Tirzepatide | Johns Hopkins University | Phase 2 | Recruiting | May 2028 |
| The Role of the Amylin Analogue Cagrilintide in Bone Metabolism | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 1 | Recruiting | May 2028 |
| Kisspeptin Administration Subcutaneously to Patients With IHH | Kisspeptin | Stephanie B. Seminara, MD | Phase 2 | Recruiting | May 2028 |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clini | Tirzepatide | Eli Lilly and Company | Phase 4 | Recruiting | May 2028 |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Tirzepatide | Eli Lilly and Company | Phase 3 | Recruiting | May 2028 |
| Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | Semaglutide | Mapi Pharma Ltd. | Phase 2 | Recruiting | May 2028 |
| Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer | Tirzepatide | Milton S. Hershey Medical Center | Observational | Recruiting | May 2028 |
| Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U | Semaglutide | VA Office of Research and Development | Phase 3 | Recruiting | Apr 2028 |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Tirzepatide | Eli Lilly and Company | Phase 3 | Recruiting | Apr 2028 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Orforglipron | Eli Lilly and Company | Phase 3 | Readout pending | Apr 2028 |
| A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Mar 2028 |
| A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Mar 2028 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 3 | Recruiting | Feb 2028 |
| A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Semaglutide, Tirzepatide | Pfizer | Phase 3 | Recruiting | Feb 2028 |
| A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes | Semaglutide | Hoffmann-La Roche | Phase 2 | Readout pending | Feb 2028 |
| A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Semaglutide | Beijing QL Biopharmaceutical Co.,Ltd | Phase 2 | Recruiting | Jan 2028 |
| Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Tirzepatide | Victor Chang Cardiac Research Institute | Phase 2 | Recruiting | Dec 2027 |
| Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide | Semaglutide | Tianjin Medical University | Observational | Recruiting | Dec 2027 |
| Short Term Effects of Semaglutide on Body Composition and Performance | Semaglutide | Morten Hostrup, PhD | Observational | Recruiting | Dec 2027 |
| A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity | Semaglutide | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 | Recruiting | Dec 2027 |
| Long-Term Effects of Semaglutide on Body Composition and Performance in Running | Semaglutide | Morten Hostrup, PhD | Observational | Recruiting | Dec 2027 |
| Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes | Tirzepatide | Universiti Sains Malaysia | Observational | Recruiting | Dec 2027 |
| Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | Semaglutide | University of Alberta | Observational | Recruiting | Dec 2027 |
| Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Tirzepatide | Weill Medical College of Cornell University | Phase 4 | Recruiting | Dec 2027 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury | Tesamorelin | Johns Hopkins University | Phase 2 | Recruiting | Dec 2027 |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | Dec 2027 |
| Functional Proteins in Polycystic Ovary Syndrome | Kisspeptin | Jagiellonian University | Observational | Recruiting | Dec 2027 |
| Efficacy of Intravenous Oxytocin to Speed Recovery After THA | Oxytocin | Wake Forest University Health Sciences | Phase 2 | Recruiting | Dec 2027 |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | Tirzepatide | National Taiwan University Clinical Trial Center | Phase 4 | Recruiting | Dec 2027 |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | CagriSema | Novo Nordisk A/S | Phase 3 | Terminated | Nov 2027 |
| A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 3 | Readout pending | Nov 2027 |
| GLP-1s to Enhance Lasting Optimal Weight | Tirzepatide | Wake Forest University Health Sciences | Phase 4 | Readout pending | Oct 2027 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 1 | Readout pending | Oct 2027 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 2 | Recruiting | Oct 2027 |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Tirzepatide | Eli Lilly and Company | Phase 3 | Recruiting | Oct 2027 |
| Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) | Tirzepatide | Dr. Md. Alimur Reza | Observational | Recruiting | Oct 2027 |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Tirzepatide | T. John Winhusen, PhD | Phase 2 | Recruiting | Sept 2027 |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Tirzepatide | Arrowhead Pharmaceuticals | Phase 2 | Recruiting | Sept 2027 |
| IBI3042 Study in Healthy Participants and Overweight or Obese Participants | Orforglipron | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Sept 2027 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 2 | Recruiting | Sept 2027 |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema | Novo Nordisk A/S | Phase 3 | Readout pending | Sept 2027 |
| Clinical Trial for Acupuncture in Adolescents With Psychological Distress and Insomnia | Oxytocin | The University of Hong Kong | Observational | Recruiting | Sept 2027 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Retatrutide | Eli Lilly and Company | Phase 3 | Readout pending | Sept 2027 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | Semaglutide | Novo Nordisk A/S | Observational | Recruiting | Aug 2027 |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | CagriSema | Novo Nordisk A/S | Phase 2 | Terminated | Aug 2027 |
| Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Semaglutide | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Aug 2027 |
| Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk | Oxytocin | Florida State University | Observational | Recruiting | Aug 2027 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Orforglipron | Eli Lilly and Company | Phase 3 | Readout pending | Aug 2027 |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Orforglipron | Eli Lilly and Company | Phase 3 | Readout pending | Aug 2027 |
| Tirzepatide in Idiopathic Intracranial Hypertension Trial | Tirzepatide | Duke University | Phase 4 | Recruiting | Aug 2027 |
| Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery | BPC-157 | University of Arkansas | Phase 1 | Recruiting | Aug 2027 |
| Tirzepatide in MetALD | Tirzepatide | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | Recruiting | Jul 2027 |
| Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study | Cerebrolysin | University Medical Centre Ljubljana | Observational | Recruiting | Jul 2027 |
| The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults | Oxytocin | Icahn School of Medicine at Mount Sinai | Observational | Terminated | Jul 2027 |
| Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Semaglutide, Tirzepatide | Ali Aminian | Phase 4 | Readout pending | Jul 2027 |
| Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity | Semaglutide | Nantes University Hospital | Observational | Recruiting | Jul 2027 |
| A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Tirzepatide | Eli Lilly and Company | Phase 4 | Readout pending | Jul 2027 |
| Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | Tirzepatide | Shahid Beheshti University of Medical Sciences | Phase 3 | Recruiting | Jun 2027 |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 3 | Recruiting | Jun 2027 |
| Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Tirzepatide | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Observational | Recruiting | Jun 2027 |
| Oxytocin in Postmenopausal Women | Oxytocin | University Hospital, Basel, Switzerland | Observational | Recruiting | Jun 2027 |
| Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients | Tirzepatide | Nanjing First Hospital, Nanjing Medical University | Observational | Recruiting | Jun 2027 |
| Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study | Tirzepatide | National Medical Research Center for Therapy and Preventive Medicine | Observational | Recruiting | Jun 2027 |
| Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Tirzepatide | Technical University of Munich | Phase 4 | Recruiting | May 2027 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Semaglutide, Tirzepatide | Eli Lilly and Company | Phase 2 | Recruiting | May 2027 |
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | Orforglipron | Eli Lilly and Company | Phase 3 | Recruiting | May 2027 |
| GLP-1R Agonist Treatment for Opioid Use Disorder | Semaglutide | Milton S. Hershey Medical Center | Phase 2 | Recruiting | Apr 2027 |
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Semaglutide, Tirzepatide | The Cleveland Clinic | Phase 4 | Readout pending | Apr 2027 |
| A Study to Evaluate ALN-2232 in Participants With Obesity | Tirzepatide | Alnylam Pharmaceuticals | Phase 2 | Recruiting | Apr 2027 |
| Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults | GHK-Cu | LifeWave, Inc. | Observational | Recruiting | Apr 2027 |
| Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia | Oxytocin | Khyber Girls Medical College | Observational | Recruiting | Apr 2027 |
| Semaglutide Therapy for Alcohol Reduction (STAR) | Semaglutide | National Institute on Drug Abuse (NIDA) | Phase 2 | Readout pending | Mar 2027 |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | CagriSema | Novo Nordisk A/S | Phase 3 | Readout pending | Mar 2027 |
| Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics | Tirzepatide | University of Wisconsin, Madison | Phase 1 | Recruiting | Mar 2027 |
| Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Semaglutide | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Recruiting | Mar 2027 |
| BPC 157 for Acute Hamstring Muscle Strain Repair | BPC-157 | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo | Melanotan-II | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| Topical GHK-Cu Gel for Acute Skin Wound Healing | GHK-Cu | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) | Tesamorelin | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | TB-500 | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | MOTS-c | Hudson Biotech | Phase 2 | Recruiting | Feb 2027 |
| Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants | Semaglutide | Terrestrial Bio, Inc. | Phase 1 | Recruiting | Feb 2027 |
| Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) | Semaglutide | Yale University | Phase 1 | Readout pending | Feb 2027 |
| A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | Semaglutide | Antag Therapeutics | Phase 2 | Recruiting | Feb 2027 |
| Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial | Cerebrolysin | Cardinal Stefan Wyszynski University | Phase 4 | Recruiting | Jan 2027 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Retatrutide | Eli Lilly and Company | Phase 1 | Readout pending | Jan 2027 |
| Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | Semaglutide | University of California, San Diego | Phase 2 | Readout pending | Dec 2026 |
| GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | Semaglutide | Insel Gruppe AG, University Hospital Bern | Observational | Recruiting | Dec 2026 |
| Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Tirzepatide | M.D. Anderson Cancer Center | Observational | Recruiting | Dec 2026 |
| Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Semaglutide, Tirzepatide | Mayo Clinic | Phase 4 | Recruiting | Dec 2026 |
| Oxytocin Pharmacokinetics and Pharmacodynamics | Oxytocin | University of Chicago | Phase 2 | Recruiting | Dec 2026 |
| Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) | Kisspeptin | Nemours Children's Clinic | Observational | Recruiting | Dec 2026 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | Tirzepatide | Eli Lilly and Company | Phase 1 | Recruiting | Dec 2026 |
| NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | Semaglutide, Tirzepatide | Istanbul Saglik Bilimleri University | Observational | Recruiting | Nov 2026 |
| GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | Semaglutide, Tirzepatide | Istanbul Saglik Bilimleri University | Observational | Recruiting | Nov 2026 |
| Tirzepatide Impact Assessment Study | Semaglutide, Tirzepatide | Texas Tech University | Observational | Recruiting | Nov 2026 |
| A Study of BGM0504 in Participants With Type 2 Diabetes | Semaglutide | BrightGene Bio-Medical Technology Co., Ltd. | Phase 3 | Readout pending | Nov 2026 |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide, Tirzepatide | Eli Lilly and Company | Phase 3 | Readout pending | Nov 2026 |
| Salivary Function and Dental Changes During GLP-1 Therapy | Semaglutide, Tirzepatide | Bilecik Seyh Edebali Universitesi | Observational | Recruiting | Oct 2026 |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin a | Retatrutide | Eli Lilly and Company | Phase 3 | Readout pending | Oct 2026 |
| Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Tirzepatide | University of New Mexico | Observational | Recruiting | Oct 2026 |
| Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation | MOTS-c | University of Gaziantep | Observational | Recruiting | Oct 2026 |
| Compare Hemodynamic Effect of Oxytocin Bolus and Infusion During Cesarean Section Under Spinal Anesthesia | Oxytocin | Hayatabad Medical Complex | Observational | Recruiting | Oct 2026 |
| Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Semaglutide, Tirzepatide | Ohio State University | Observational | Recruiting | Oct 2026 |
| Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness | Cerebrolysin | Konkuk University Medical Center | Phase 4 | Recruiting | Sept 2026 |
| Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | Semaglutide | Vanderbilt University Medical Center | Phase 2 | Readout pending | Sept 2026 |
| A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 1 | Readout pending | Sept 2026 |
| Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance | Semaglutide | ETH Zurich | Observational | Completed | Sept 2026 |
| A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least | Tirzepatide | Hoffmann-La Roche | Phase 2 | Readout pending | Sept 2026 |
| Comparing Facial Aging Between Identical Twins With 3D Imaging | Semaglutide, Tirzepatide | Ponsky Facial Aesthetics And Plastic Surgery, Llc | Observational | Recruiting | Sept 2026 |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Retatrutide, Semaglutide | Eli Lilly and Company | Phase 3 | Readout pending | Aug 2026 |
| Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Semaglutide | Rezera (formerly NodThera Limited) | Phase 2 | Completed | Aug 2026 |
| BPC-157 microneedle patch | BPC-157 | Independent academic | Phase 2 | Recruiting | Aug 2026 |
| Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity | Oxytocin | Wake Forest University Health Sciences | Phase 2 | Terminated | Aug 2026 |
| Effect of Itopride on Semaglutide Gastroparesis | Semaglutide | Ain Shams University | Phase 4 | Completed | Jul 2026 |
| A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Jul 2026 |
| A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | Semaglutide | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Completed | Jul 2026 |
| Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction | Semaglutide | Mayo Clinic | Phase 4 | Completed | Jul 2026 |
| Probiotics in Obese Patients Treated With Semaglutide | Semaglutide | Nordic Biotic Sp. z o.o. | Observational | Completed | Jul 2026 |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Tirzepatide | Eli Lilly and Company | Phase 2 | Completed | Jul 2026 |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Tirzepatide | Eli Lilly and Company | Phase 2 | Completed | Jul 2026 |
| KPV in UC · open-label extension | KPV | Investigator-initiated | Observational | Recruiting | Jun 2026 |
| A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 3 | Completed | Jun 2026 |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | CagriSema | Novo Nordisk A/S | Phase 2 | Completed | Jun 2026 |
| AT1001 for the Treatment of Long COVID | Larazotide | Massachusetts General Hospital | Phase 2 | Completed | Jun 2026 |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Retatrutide | Eli Lilly and Company | Phase 3 | Completed | Jun 2026 |
| Weight Loss in Adults Using Semaglutide (Real-world Study) | Semaglutide | Novo Nordisk A/S | Observational | Completed | Jun 2026 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Tirzepatide, CagriSema | Novo Nordisk A/S | Phase 3 | Completed | Jun 2026 |
| Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain | Oxytocin | Wake Forest University Health Sciences | Phase 2 | Completed | Jun 2026 |
| SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary | Semaglutide | Novo Nordisk A/S | Observational | Completed | May 2026 |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Retatrutide | Eli Lilly and Company | Phase 1 | Completed | May 2026 |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Retatrutide | Eli Lilly and Company | Phase 3 | Completed | Apr 2026 |
| Effects of Warm Shower on Lactation, Fatigue, and Maternal Burnout | Oxytocin | KTO Karatay University | Observational | Completed | Apr 2026 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Retatrutide | Eli Lilly and Company | Phase 3 | Completed | Apr 2026 |
| CERebrolysin In CADASIL | Cerebrolysin | Ever Neuro Pharma GmbH | Phase 2 | Readout pending | Mar 2026 |
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Semaglutide, Tirzepatide | Zagazig University | Phase 3 | Completed | Mar 2026 |
| A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Semaglutide | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Completed | Mar 2026 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Tirzepatide, CagriSema | Novo Nordisk A/S | Phase 3 | Completed | Mar 2026 |
| A Study of BGM0504 in Participants With Obesity | Tirzepatide | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Completed | Jan 2026 |
| Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy | Cerebrolysin | October 6 University | Phase 2 | Recruiting | Jan 2026 |
| Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Semaglutide, Tirzepatide | Brigham and Women's Hospital | Observational | Completed | Dec 2025 |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 3 | Completed | Nov 2025 |
| A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery | BPC-157 | Parlay Wellness | Observational | Completed | Nov 2025 |
| Semaglutide in Women With Polycystic Ovary Syndrome and Obesity | Semaglutide | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 3 | Completed | Oct 2025 |
| A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Semaglutide | Novo Nordisk A/S | Phase 3 | Readout pending | Oct 2025 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | CagriSema | Novo Nordisk A/S | Phase 3 | Completed | Oct 2025 |
| A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Sept 2025 |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide a | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 2 | Completed | Sept 2025 |
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Sept 2025 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | CagriSema | Novo Nordisk A/S | Phase 3 | Completed | Sept 2025 |
| Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism | Kisspeptin | Stephanie B. Seminara, MD | Phase 2 | Completed | Aug 2025 |
| A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron, Semaglutide | Eli Lilly and Company | Phase 3 | Completed | Aug 2025 |
| A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Aug 2025 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Orforglipron | Eli Lilly and Company | Phase 3 | Readout pending | Jul 2025 |
| A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Jun 2025 |
| Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study | Cerebrolysin | Yonsei University | Phase 4 | Recruiting | Jun 2025 |
| Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU | Cerebrolysin | Ain Shams University | Phase 3 | Completed | May 2025 |
| The Effect of Simulation-Based Oxytocin Induction Training on Midwifery Students' Knowledge and Anxiety Levels | Oxytocin | Melisa Gündeş | Observational | Completed | May 2025 |
| Body Composition and Adipose Tissue in HIV | Tesamorelin | Columbia University | Phase 4 | Terminated | Apr 2025 |
| A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide | Novo Nordisk A/S | Phase 3 | Completed | Apr 2025 |
| A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects. | Semaglutide | Second Affiliated Hospital of Soochow University | Phase 2 | Completed | Apr 2025 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Orforglipron | Eli Lilly and Company | Phase 3 | Completed | Apr 2025 |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 1 | Completed | Mar 2025 |
| A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy | Semaglutide | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Observational | Completed | Mar 2025 |
| GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation | Semaglutide | West China Hospital | Observational | Terminated | Dec 2024 |
| The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease | MK-677 (Ibutamoren) | Massachusetts General Hospital | Phase 2 | Completed | Nov 2024 |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Semaglutide, CagriSema | Novo Nordisk A/S | Phase 3 | Readout pending | Oct 2024 |
| A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities | Orforglipron | Eli Lilly and Company | Phase 1 | Completed | Jul 2024 |
| A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | Orforglipron | Eli Lilly and Company | Phase 1 | Completed | Jul 2024 |
| Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Tesamorelin | Massachusetts General Hospital | Phase 2 | Completed | Jul 2024 |
| Recall by Genotype: Neuropeptide Stimulation | Kisspeptin | Stephanie B. Seminara, MD | Phase 1 | Terminated | May 2024 |
| Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness | Cerebrolysin | Ever Neuro Pharma GmbH | Observational | Completed | Apr 2024 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons | Tesamorelin | University of California, San Diego | Phase 2 | Completed | Oct 2023 |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Semaglutide | Novo Nordisk A/S | Phase 3 | Completed | Jul 2023 |
| Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) | Tesofensine | Saniona | Phase 2 | Terminated | Dec 2022 |
| Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome | Tesofensine | Saniona | Phase 2 | Terminated | Dec 2022 |
| Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test | Kisspeptin | Massachusetts General Hospital | Phase 1 | Completed | Oct 2022 |
| Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream | Argireline | Wayne State University | Observational | Completed | Oct 2022 |
| Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms | Larazotide | 9 Meters Biopharma, Inc. | Phase 3 | Terminated | Jul 2022 |
| Growth Hormone Dynamics and Cardiac Steatosis in HIV | Tesamorelin | Massachusetts General Hospital | Observational | Completed | Apr 2022 |
| 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) | Tesofensine | Saniona | Phase 2 | Completed | Oct 2020 |
| Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD | MOTS-c | University of Athens | Observational | Active | Dec 2019 |
| Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS) | Tesofensine | Saniona | Phase 2 | Completed | Jul 2019 |
| A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate | Tesofensine | Saniona | Phase 1 | Completed | Jun 2019 |
| Tesamorelin Effects on Liver Fat and Histology in HIV | Tesamorelin | Massachusetts General Hospital | Observational | Completed | Jan 2019 |
| Study to Investigate the Pharmacokinetic Profile | Tesofensine | Saniona | Phase 1 | Completed | Feb 2018 |
| Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus | Tesofensine | Saniona | Phase 2 | Completed | Jan 2017 |
| 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | PT-141 | Palatin Technologies, Inc | Phase 3 | Completed | Aug 2016 |
| 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | PT-141 | Palatin Technologies, Inc | Phase 3 | Completed | Jul 2016 |
| Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin | Argireline | University of California, Davis | Observational | Completed | Feb 2016 |
| PCO-02 - Safety and Pharmacokinetics Trial | BPC-157 | PharmaCotherapia d.o.o. | Phase 1 | Active | Feb 2016 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | P21 | Cellceutix Corporation | Phase 1 | Completed | Jan 2016 |
| Acetyl Hexapeptide-8 for Blepharospasm | Argireline | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | Terminated | May 2015 |
| Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder | PT-141 | Palatin Technologies, Inc | Phase 2 | Completed | Sept 2012 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm | Argireline | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | Completed | Oct 2010 |
| Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects | MK-677 (Ibutamoren) | University of Virginia | Phase 2 | Terminated | Apr 2010 |
| Argireline in Treatment of Periorbital Wrinkles | Argireline | Mahidol University | Phase 3 | Completed | Sept 2009 |
| Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients | MK-677 (Ibutamoren) | University of Virginia | Observational | Completed | Jan 2009 |
| TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Tesamorelin | Theratechnologies | Phase 3 | Completed | Oct 2008 |
| Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia | MK-677 (Ibutamoren) | Bennett, Robert, M.D. | Phase 2 | Completed | Jan 2008 |
| An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type | Tesofensine | Boehringer Ingelheim | Phase 2 | Completed | Mar 2005 |
| Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults | MK-677 (Ibutamoren) | University of Virginia | Phase 2 | Completed | Jun 2004 |
How to read this, and what it is not
Readout dates are sponsor expectations drawn from registry records. They slip routinely, and a date moving is itself information. Terminated programmes are shown rather than removed — a trial that stopped usually tells you more than one that is merely slow.
A trial existing is not evidence that a compound works. Phase 1 and 2 results are not Phase 3 results, and most compounds that reach a registry never reach a label. For what the evidence currently supports, each molecule links through to its own page and our evidence-tier framework.
Tracking what people report about these compounds outside the trials — demand, tolerability and discontinuation across Reddit and X — is what we are building in Peptide Signal.